Weekly Recap: Q3 revenue and EPS beat estimates and 2026 capex plan

What happened

HCA Healthcare reported Q3 revenue of $19.85 billion, up 3.6%, and adjusted earnings per share of $7.22, above the $6.66 estimate. Shares fell over 5% after its 2027 earnings outlook was broadly in line with 2026. HCA plans $5.0B–$5.5B in 2026 capital spending.

Confirmed

Global impact / market context

The results show stronger-than-estimated recent revenue and earnings, but the broadly flat 2027 outlook may limit expectations for near-term profit growth. The planned capital spending directs substantial funds toward HCA’s operations, while potentially reducing cash available for other uses; the article gives no project-level breakdown.

Analyst inference

The share decline after the outlook suggests investors focused more on expected earnings growth than on the Q3 beat. RBC raised its price target to $521 while keeping an Outperform rating; a price target is an analyst’s estimate, not a guaranteed share price. The article gives no reason for the change.

Analyst inference

What to watch

1. Watch HCA’s next outlook for whether management gives clearer evidence of earnings growth beyond 2026, since the current forecast is broadly flat against that year. Analyst inference
2. Track whether planned 2026 capital spending stays within the stated $5.0B–$5.5B range and how the company describes its intended uses; acquisitions are excluded. Confirmed
3. Observe whether future results show revenue and adjusted earnings continuing to grow, and whether that performance changes investor concern about the flat 2027 outlook. Analyst inference

Evidence

• Original source link unavailable